National Cancer Center Hospital ( Site 1750)

Chuo-ku, Tokyo 104-0045

0 studies enrolling now · 1 studies all time

What they study most

Melanoma

Studies at this site

• A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) — Completed